Palliative care 2017

Flaire after discontinuation of TKI

• Some patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib (RECIST progression after initial benefit) have accelerated progression of disease after discontinuation of TKI • 14/61 patients experienced a disease flair with a median of 8 days (range 3–21) after discontinuation